Questions Grow Over Coronavirus Vax Trials
The drugmaker AstraZeneca is pushing back after experts questioned the quality of the company’s coronavirus vaccine tests.
A company spokesperson said Thursday that their vaccine clinical trials were “conducted to the highest standards.” That included oversight by a data and safety monitoring board that found “the analysis … [showed] protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine.” . . .
Researchers have been raising concerns ever since AstraZeneca and its partner, the University of Oxford, announced Monday that their jab is approximately 70 percent effective. The news was especially welcome since this vaccine could be cheaper and easier to roll out to low and middle income countries than others, but left experts questioning the company’s findings.
The assessment issued Monday was based on data from two groups: One had nearly 9,000 people who received two full doses of the vaccine, which produced a 62 percent efficacy rate, while a smaller group of 2,741 received a half-dose followed by a full dose, which produced 90 percent efficacy. (Read more from “Questions Grow Over Coronavirus Vax Trials” HERE)
Follow Joe Miller on Twitter HERE and Facebook HERE
